Key Drivers
- Cash Cushion
- No Revenue
- R&D Burn
AIAI Summary
ANNX has shifted from a speculative biotech story to a late-stage, binary catalyst bet with two near-registration assets and enough cash to fund the next phase, but the stock likely won't re-rate until tanruprubart and vonaprument convert early signals into clean, durable regulatory data fast enough to justify the ongoing burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •No Revenue
- •R&D Burn
ANNX has a strong cash-rich balance sheet and modest leverage, but the lack of revenue, persistent losses, and heavy R&D-driven cash burn continue to pressure fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Tight range
- •Base forming
- •Resistance capped
ANNX has been drifting lower over the last month but is trying to base in a tight $5.25–$5.60 range, with near-term support at $5.25–$5.30 and a breakout only improving if it can reclaim $5.60.
Rally to $5.60 on 2026-08-06 faded quickly
Sentiment & News
Key News Insights:
- •GBS Data
- •Cash Runway
- •ARCHER II
Annexon boosted its financial runway and advanced key late-stage programs, highlighted by positive tanruprubart GBS data, a Q4 BLA target, and an expanded ARCHER II design for longer-term efficacy assessment.
This is modestly positive for Annexon as it strengthens financing while keeping multiple clinical catalysts on track
Similar Companies in Healthcare
Other companies in the same sector with AI ratings